Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
annika.jodicke@ndorms.ox.ac.uk

ORCID
https://orcid.org/0000-0002-0000-0110

Pronouns
she/her

Research groups

Annika Jödicke

Dr. sc. ETH

Senior Researcher in Pharmacoepidemiology

Pharmacoepidemiology | Real-World Evidence

My work as a pharmacoepidemiologist is to improve healthcare for patients by using de-identified healthcare data to generate robust and reliable real-world evidence on the utilisation, safety and effectiveness of medicines.

I am a pharmacist by training, and joined the Health Data Sciences Group in 2020 after completing my doctoral training at ETH Zurich, Switzerland.

Several of my projects use data from across Europe, mapped to the OMOP common data model. I have a particular research interest and expertise in geriatric pharmacoepidemiology, vaccine effectiveness research and regulatory pharmacoepidemiology.

My areas of work include conducting causal inference and drug utilisation studies for the national and European regulators (e.g. in the context of DARWIN EU) as well as methodological work to minimize confounding bias in observational studies.

Since May 2025, I am honoured to co-lead with Prof. Prieto-Alhambra the academic side of the Innovative Health Initiative’s GREG project to generate, pilot-test, and disseminate evidence-based guidance for the use of real-world evidence to support regulatory and HTA decision-making.

Recent publications

Secular Trends in the Use of Valproate-Containing Medicines in Women of Childbearing Age in Europe: A Multinational DARWIN EU Network Study.

Bellas L. et al, (2025), Pharmacoepidemiol Drug Saf, 34

Clusters of post-acute COVID-19 symptoms: a latent class analysis across 9 databases and 7 countries.

López-Güell K. et al, (2025), J Clin Epidemiol, 185

Trends in prescription opioid use in Europe: A DARWIN EU® multinational cohort study including seven European countries.

Xie J. et al, (2025), Front Pharmacol, 16

Development of the ECHOES national dataset: a resource for monitoring post-acute and long-term COVID-19 health outcomes in England.

Allen H. et al, (2025), Front Public Health, 13

Standardised and Reproducible Phenotyping Using Distributed Analytics and Tools in the Data Analysis and Real World Interrogation Network (DARWIN EU).

Dernie F. et al, (2024), Pharmacoepidemiol Drug Saf, 33

Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data.

Xie J. et al, (2024), EClinicalMedicine, 77

Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones.

Guo Y. et al, (2024), Pharmacoepidemiol Drug Saf, 33

Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID-19 Pandemic.

Mercadé-Besora N. et al, (2024), Arthritis Care Res (Hoboken), 76, 1173 - 1178

Calculating daily dose in the Observational Medical Outcomes Partnership Common Data Model.

Burkard T. et al, (2024), Pharmacoepidemiol Drug Saf, 33

Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes.

Xie J. et al, (2024), Nat Commun, 15

Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway.

Trinh NT. et al, (2024), Lancet Respir Med, 12, e33 - e34

The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications.

Mercadé-Besora N. et al, (2024), Heart, 110, 635 - 643

The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia.

Català M. et al, (2024), Lancet Respir Med, 12, 225 - 236

Observational methods for COVID-19 vaccine effectiveness research: an empirical evaluation and target trial emulation.

Català M. et al, (2024), Int J Epidemiol, 53

Machine learning methods for propensity and disease risk score estimation in high-dimensional data: a plasmode simulation and real-world data cohort analysis.

Guo Y. et al, (2024), Front Pharmacol, 15

Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: a cohort study.

Barclay NL. et al, (2024), Ther Adv Med Oncol, 16

The impact of the UK COVID-19 lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: a population-based cohort study.

Barclay NL. et al, (2024), Front Oncol, 14

Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study.

Gauffin O. et al, (2023), Drug Saf, 46, 1335 - 1352

"The burden of post-acute COVID-19 symptoms in a multinational network cohort analysis".

Kostka K. et al, (2023), Nat Commun, 14

Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: implications for bone health

Barclay NL. et al, (2023)

Drug utilization analysis of osteoporosis medications in seven European electronic health databases.

Tan EH. et al, (2023), Osteoporos Int, 34, 1771 - 1781

Risk of adverse events following the initiation of antihypertensives in older people with complex health needs: a self-controlled case series in the United Kingdom.

Jödicke AM. et al, (2023), Age Ageing, 52

HLA alleles, COVID-19 vaccine antibody response and real-world breakthrough outcomes

Xie J. et al, (2023)

The role of COVID-19 vaccines in preventing post COVID-19 thromboembolic and cardiovascular complications: a multinational cohort study

Mercadé-Besora N. et al, (2023)

The Effectiveness of COVID-19 Vaccines to Prevent Long COVID Symptoms: Staggered Cohort Analyses of Data from the UK, Spain, and Estonia

Catala Sabate M. et al, (2023)

The burden of long COVID: a multinational cohort analysis of Spanish and UK data including SARS-CoV-2 infections, reinfections, and matched contemporaneous test negative controls

Prieto Alhambra D. et al, (2023)

Characterising complex health needs and the use of preventive therapies in the older population: a population-based cohort analysis of UK primary care and hospital linked data.

Elhussein L. et al, (2023), BMC Geriatr, 23

Characterising the treatment of thromboembolic events after COVID-19 vaccination in 4 European countries and the US: An international network cohort study.

Markus AF. et al, (2023), Front Pharmacol, 14

The Impact of the UK COVID-19 Lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: a population-based cohort study

Barclay N. et al, (2023)

Observational methods for COVID-19 vaccine effectiveness research: a trial emulation and empirical evaluation

Català M. et al, (2022)

Characterising complex health needs and the use of preventative therapies in the older population: a population-based cohort analysis of UK primary care and hospital linked data

Elhussein L. et al, (2022)

Oral Bisphosphonates Are Associated With Increased Risk of Severe Acute Kidney Injury in Elderly Patients With Complex Health Needs: A Self-Controlled Case Series in the United Kingdom.

Oda T. et al, (2022), J Bone Miner Res, 37, 1270 - 1278

Treatment patterns for osteoporosis medications in five European countries: a multinational real world cohort analysis

Robinson D. et al, (2022), Osteoporosis International, 32

The impact of COVID-19 on population-level drug utilization of alendronate

Tan EH. et al, (2022), Osteoporosis International, 32, 314 - 315

Validation of Algorithms to Identify Acute Myocardial Infarction, Stroke, and Cardiovascular Death in German Health Insurance Data.

Platzbecker K. et al, (2022), Clin Epidemiol, 14, 1351 - 1361

The risk of severe acute kidney injury with use of anti-hypertensives in the elderly: A self-controlled case series analysis

Tan EHC. et al, (2022), PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 31, 633 - 634

Bisphosphonate use and risk of severe acute kidney injury: a self-controlled case series in frail elderly patients in the UK

Oda T. et al, (2021), Pharmacoepidemiology and Drug Safety, 30, 19 - 19

Fracture risk following the initiation of antihypertensive therapy amongst frail elderly people: a self-controlled case series analysis

Jodicke A. et al, (2021), Pharmacoepidemiology and Drug Safety, 30, 232 - 232

bstracts of the 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, August 23, 2021.

(2021), Pharmacoepidemiol Drug Saf, 30 Suppl 1, 3 - 439

Use of and adherence to bisphosphonates in elderly patients with complex health needs: an analysis of UK primary care records

ELHUSSEIN L. et al, (2021)

More publications